{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:28:33Z","timestamp":1778898513104,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["FIS 17\/551"],"award-info":[{"award-number":["FIS 17\/551"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s13760-020-01516-x","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T15:03:19Z","timestamp":1602514999000},"page":"1767-1775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-6938","authenticated-orcid":false,"given":"Antonio","family":"Barreiro-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-8087","authenticated-orcid":false,"given":"Maria T.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0021-3041","authenticated-orcid":false,"given":"Sara","family":"Carratal\u00e0-Bosc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3767-3738","authenticated-orcid":false,"given":"Francisco","family":"P\u00e9rez-Miralles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-7579","authenticated-orcid":false,"given":"Carmen","family":"Alcal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0809-8279","authenticated-orcid":false,"given":"Enrique","family":"Espa\u00f1a-Gregori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-925X","authenticated-orcid":false,"given":"Bonaventura","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/s-0036-1579692","volume":"36","author":"F Costello","year":"2016","unstructured":"Costello F (2016) Vision disturbances in multiple sclerosis. Semin Neurol 36:185\u2013195. https:\/\/doi.org\/10.1055\/s-0036-1579692","journal-title":"Semin Neurol"},{"key":"1516_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","volume":"115","author":"Optic Neuritis Study Group","year":"2008","unstructured":"Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 115:1079\u20131082. https:\/\/doi.org\/10.1016\/j.ophtha.2007.08.004","journal-title":"Ophthalmology"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1177\/1352458508088916","volume":"14","author":"C Heesen","year":"2008","unstructured":"Heesen C, B\u00f6hm J, Reich C, Kasper J, Goebel M, Gold SM (2008) Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 14:988\u2013991. https:\/\/doi.org\/10.1177\/1352458508088916","journal-title":"Mult Scler"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"e0195856","DOI":"10.1371\/journal.pone.0195856","volume":"13","author":"B Sanchez-Dalmau","year":"2018","unstructured":"Sanchez-Dalmau B, Martinez-Lapiscina EH, Pulido-Valdeolivas I et al (2018) Predictors of vision impairment in multiple sclerosis. PLoS ONE 13:e0195856. https:\/\/doi.org\/10.1371\/journal.pone.0195856","journal-title":"PLoS ONE"},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ceo.12751","volume":"45","author":"SL Graham","year":"2016","unstructured":"Graham SL, Klistorner A (2016) Afferent visual pathways in multiple sclerosis: a review. Clin Exp Ophthalmol 45:62\u201372. https:\/\/doi.org\/10.1111\/ceo.12751","journal-title":"Clin Exp Ophthalmol"},{"key":"1516_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/brain\/awq346","volume":"134","author":"S Saidha","year":"2011","unstructured":"Saidha S, Syc SB, Ibrahim MA et al (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 134:518\u2013533. https:\/\/doi.org\/10.1093\/brain\/awq346","journal-title":"Brain"},{"key":"1516_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1212\/WNL.0b013e3182a3525e","volume":"81","author":"S Ortiz-P\u00e9rez","year":"2013","unstructured":"Ortiz-P\u00e9rez S, Mart\u00ednez-Lapiscina EH, Gabilondo I et al (2013) Retinal periphlebitis is associated with multiple sclerosis severity. Neurology 81:877\u2013881. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a3525e","journal-title":"Neurology"},{"key":"1516_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519872751","author":"J Lambe","year":"2019","unstructured":"Lambe J, Saidha S, Bermel RA (2019) Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials. Mult Scler. https:\/\/doi.org\/10.1177\/1352458519872751","journal-title":"Mult Scler"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11940-017-0452-7","volume":"19","author":"AU Brandt","year":"2017","unstructured":"Brandt AU, Martinez-Lapiscina EH, Nolan R, Saidha S (2017) Monitoring the course of multiple sclerosis with optical coherence tomography. Curr Treat Options Neurol 19:15. https:\/\/doi.org\/10.1007\/s11940-017-0452-7","journal-title":"Curr Treat Options Neurol"},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1352458517690822","volume":"23","author":"LJ Balcer","year":"2017","unstructured":"Balcer LJ, Raynowska J, Nolan R et al (2017) Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler 23:734\u2013747. https:\/\/doi.org\/10.1177\/1352458517690822","journal-title":"Mult Scler"},{"key":"1516_CR11","first-page":"658","volume":"93","author":"B Katz","year":"1995","unstructured":"Katz B (1995) The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans Am Ophthalmol Soc 93:658\u2013708","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1516_CR12","first-page":"1895","volume":"31","author":"S Silverman","year":"1990","unstructured":"Silverman S, Hart W Jr, Gordon M, Kilo C (1990) The dyschromatopsia of optic neuritis is determined in part by the foveal\/perifoveal distribution of visual field damage. Invest Ophthalmol Vis Sci 31:1895\u20131902","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1516_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrn2094","volume":"8","author":"SG Solomon","year":"2007","unstructured":"Solomon SG, Lennie P (2007) The machinery of colour vision. Nat Rev Neurosci 8:276\u2013286. https:\/\/doi.org\/10.1038\/nrn2094","journal-title":"Nat Rev Neurosci"},{"key":"1516_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/brain\/119.3.723","volume":"119","author":"V Porciatti","year":"1996","unstructured":"Porciatti V, Sartucci F (1996) Retinal and cortical evoked responses to chromatic contrast stimuli. specific losses in both eyes of patients with multiple sclerosis and unilateral optic neuritis. Brain 119:723\u2013740. https:\/\/doi.org\/10.1093\/brain\/119.3.723","journal-title":"Brain"},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/brain\/124.9.1813","volume":"124","author":"N Evangelou","year":"2001","unstructured":"Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124:1813\u20131820. https:\/\/doi.org\/10.1093\/brain\/124.9.1813","journal-title":"Brain"},{"key":"1516_CR16","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00415-015-7876-3","volume":"262","author":"EJ Lampert","year":"2015","unstructured":"Lampert EJ, Andorra M, Torres-Torres R et al (2015) Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. J Neurol 262:2491\u20132497. https:\/\/doi.org\/10.1007\/s00415-015-7876-3","journal-title":"J Neurol"},{"key":"1516_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"key":"1516_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1186\/1756-0500-7-910","volume":"7","author":"EH Mart\u00ednez-Lapiscina","year":"2014","unstructured":"Mart\u00ednez-Lapiscina EH, Fraga-Pumar E, Gabilondo I et al (2014) The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. BMC Res Notes 7:910. https:\/\/doi.org\/10.1186\/1756-0500-7-910","journal-title":"BMC Res Notes"},{"key":"1516_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ana.24030","volume":"75","author":"I Gabilondo","year":"2014","unstructured":"Gabilondo I, Mart\u00ednez-Lapiscina EH, Mart\u00ednez-Heras E et al (2014) Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol 75:98\u2013107. https:\/\/doi.org\/10.1002\/ana.24030","journal-title":"Ann Neurol"},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"e1005757","DOI":"10.1371\/journal.pcbi.1005757","volume":"13","author":"E Kotelnikova","year":"2017","unstructured":"Kotelnikova E, Kiani NA, Abad E et al (2017) Dynamics and heterogeneity of brain damage in multiple sclerosis. PLoS Comput Biol 13:e1005757. https:\/\/doi.org\/10.1371\/journal.pcbi.1005757","journal-title":"PLoS Comput Biol"},{"key":"1516_CR21","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1944\u20131952. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"1516_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1755-3768.1982.tb00621.x","volume":"60","author":"KJ Bowman","year":"1982","unstructured":"Bowman KJ (1982) A method for quantitative scoring of the Farnsworth panel D-15. Acta Ophthalmol 60:907\u2013916. https:\/\/doi.org\/10.1111\/j.1755-3768.1982.tb00621.x","journal-title":"Acta Ophthalmol"},{"key":"1516_CR23","first-page":"50","volume":"29","author":"AJ Vingrys","year":"1988","unstructured":"Vingrys AJ, King-Smith PE (1988) A quantitative scoring technique for panel tests of color vision. Invest Ophthalmol Vis Sci 29:50\u201363","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","volume":"7","author":"P Tewarie","year":"2012","unstructured":"Tewarie P, Balk L, Costello F et al (2012) The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE 7:e34823. https:\/\/doi.org\/10.1371\/journal.pone.0034823","journal-title":"PLoS ONE"},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1352458514538110","volume":"21","author":"S Schippling","year":"2015","unstructured":"Schippling S, Balk LJ, Costello F et al (2015) Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler 21:163\u2013170. https:\/\/doi.org\/10.1177\/1352458514538110","journal-title":"Mult Scler"},{"key":"1516_CR26","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","volume":"88","author":"A Cruz-Herranz","year":"2016","unstructured":"Cruz-Herranz A, Balk J, Oberwahrenbrock T et al (2016) The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 88:2303\u20132309. https:\/\/doi.org\/10.1212\/WNL.0000000000002774","journal-title":"Neurology"},{"key":"1516_CR27","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1177\/1352458511418630","volume":"17","author":"S Saidha","year":"2011","unstructured":"Saidha S, Syc SB, Durbin MK et al (2011) Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler 17:1449\u20131463. https:\/\/doi.org\/10.1177\/1352458511418630","journal-title":"Mult Scler"},{"key":"1516_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2015.10.008","volume":"5","author":"R Behbehani","year":"2016","unstructured":"Behbehani R, Al-Moosa A, Sriraman D, Alroughani R (2016) Ganglion cell analysis in acute optic neuritis. Mult Scler Relat Disord 5:66\u201369. https:\/\/doi.org\/10.1016\/j.msard.2015.10.008","journal-title":"Mult Scler Relat Disord"},{"key":"1516_CR29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/oem.57.9.582","volume":"57","author":"S Semple","year":"2000","unstructured":"Semple S, Dick F, Osborne A et al (2000) Impairment of colour vision in workers exposed to organic solvents. Occup Environ Med 57:582\u2013587. https:\/\/doi.org\/10.1136\/oem.57.9.582","journal-title":"Occup Environ Med"},{"key":"1516_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1017\/S0952523808080437","volume":"25","author":"A Moura","year":"2008","unstructured":"Moura A, Teixeira R, Oiwa N et al (2008) Chromatic discrimination losses in multiple sclerosis patients with and without optic neuritis using the Cambridge Colour Test. Vis Neurosci 25:463\u2013468. https:\/\/doi.org\/10.1017\/S0952523808080437","journal-title":"Vis Neurosci"},{"key":"1516_CR31","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1177\/1352458513517591","volume":"20","author":"EH Mart\u00ednez-Lapiscina","year":"2014","unstructured":"Mart\u00ednez-Lapiscina EH, Ortiz-P\u00e9rez S, Fraga-Pumar E et al (2014) Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler 20:1207\u20131216. https:\/\/doi.org\/10.1177\/1352458513517591","journal-title":"Mult Scler"},{"key":"1516_CR32","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/1352458511431972","volume":"18","author":"P Villoslada","year":"2012","unstructured":"Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A (2012) Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler 18:991\u2013999. https:\/\/doi.org\/10.1177\/1352458511431972","journal-title":"Mult Scler"},{"key":"1516_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jocn.2018.11.011","volume":"61","author":"B Yuksel","year":"2019","unstructured":"Yuksel B, Dogan B, Koctekin B et al (2019) Color vision testing versus pattern visual evoked potentials and optical coherence tomography parameters in subclinical optic nerve involvement in multiple sclerosis. J Clin Neurosci 61:48\u201353. https:\/\/doi.org\/10.1016\/j.jocn.2018.11.011","journal-title":"J Clin Neurosci"},{"key":"1516_CR34","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ophtha.2017.01.005","volume":"124","author":"E Garcia-Martin","year":"2017","unstructured":"Garcia-Martin E, Ara JR, Martin J et al (2017) Retinal and optic nerve degeneration in patients with multiple sclerosis followed up for 5 years. Ophthalmology 124:688\u2013696. https:\/\/doi.org\/10.1016\/j.ophtha.2017.01.005","journal-title":"Ophthalmology"},{"key":"1516_CR35","doi-asserted-by":"publisher","first-page":"8344","DOI":"10.1167\/iovs.12-10362","volume":"53","author":"R Herrero","year":"2012","unstructured":"Herrero R, Garcia-Martin E, Almarcegui C et al (2012) Progressive degeneration of the retinal nerve fiber layer in patients with multiple sclerosis. Invest Ophthalmol Vis Sci 53:8344\u20138349. https:\/\/doi.org\/10.1167\/iovs.12-10362","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1516_CR36","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1212\/WNL.0000000000001257","volume":"84","author":"J Oh","year":"2015","unstructured":"Oh J, Sotirchos ES, Saidha S et al (2015) Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. Neurology 84:720\u2013728. https:\/\/doi.org\/10.1212\/WNL.0000000000001257","journal-title":"Neurology"},{"key":"1516_CR37","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","volume":"389","author":"D Ontaneda","year":"2017","unstructured":"Ontaneda D, Thompson AJ, Fox RJ et al (2017) Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet 389:1357\u20131366. https:\/\/doi.org\/10.1016\/S0140-6736(16)31320-4","journal-title":"Lancet"},{"key":"1516_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s13311-016-0479-6","volume":"14","author":"D Ontaneda","year":"2017","unstructured":"Ontaneda D, Fox RJ (2017) Imaging as an outcome measure in multiple sclerosis. Neurotherapeutics 14:24\u201334. https:\/\/doi.org\/10.1007\/s13311-016-0479-6","journal-title":"Neurotherapeutics"},{"key":"1516_CR39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrneurol.2015.80","volume":"11","author":"H Kearney","year":"2015","unstructured":"Kearney H, Miller DH, Ciccarelli O (2015) Spinal cord MRI in multiple sclerosis\u2014diagnostic, prognostic and clinical value. Nat Rev Neurol 11:327\u2013338. https:\/\/doi.org\/10.1038\/nrneurol.2015.80","journal-title":"Nat Rev Neurol"},{"key":"1516_CR40","doi-asserted-by":"publisher","first-page":"175628641984059","DOI":"10.1177\/1756286419840593","volume":"12","author":"M Moccia","year":"2019","unstructured":"Moccia M, Ruggieri S, Ianniello A et al (2019) Advances in spinal cord imaging in multiple sclerosis. Ther Adv Neurol Disord 12:1756286419840593. https:\/\/doi.org\/10.1177\/1756286419840593","journal-title":"Ther Adv Neurol Disord"},{"key":"1516_CR41","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1212\/WNL.0000000000005853","volume":"91","author":"C Tsagkas","year":"2018","unstructured":"Tsagkas C, Magon S, Gaetano L et al (2018) Spinal cord volume loss: a marker of disease progression in multiple sclerosis. Neurology 91:e349\u2013e358. https:\/\/doi.org\/10.1212\/WNL.0000000000005853","journal-title":"Neurology"},{"key":"1516_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi I, Lassmann H (2017) Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 88:137\u2013145. https:\/\/doi.org\/10.1136\/jnnp-2016-313300","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1516_CR43","doi-asserted-by":"publisher","first-page":"e0157293","DOI":"10.1371\/journal.pone.0157293","volume":"11","author":"M Satue","year":"2016","unstructured":"Satue M, Rodrigo MJ, Otin S et al (2016) Relationship between visual dysfunction and retinal changes in patients with multiple sclerosis. PLoS ONE 11:e0157293. https:\/\/doi.org\/10.1371\/journal.pone.0157293","journal-title":"PLoS ONE"},{"key":"1516_CR44","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1007\/s00415-019-09246-8","volume":"266","author":"N Levin","year":"2019","unstructured":"Levin N, Devereux M, Bick A, Baker N, Green A (2019) Color perception impairment following optic neuritis and its association with retinal atrophy. J Neurol 266:1160\u20131166. https:\/\/doi.org\/10.1007\/s00415-019-09246-8","journal-title":"J Neurol"},{"key":"1516_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0301-4738.99842","volume":"61","author":"FC Gundogan","year":"2013","unstructured":"Gundogan FC, Tas A, Altun S, Oz O, Erdem U, Sobaci G (2013) Color vision versus pattern visual evoked potentials in the assessment of subclinical optic pathway involvement in multiple sclerosis. Indian J Ophthalmol 61:100\u2013103. https:\/\/doi.org\/10.4103\/0301-4738.99842","journal-title":"Indian J Ophthalmol"},{"key":"1516_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1444-0938.2006.00015.x","volume":"89","author":"BL Cole","year":"2006","unstructured":"Cole BL, Lian KY, Lakkis C (2006) The new Richmond HRR pseudoisochromatic test for colour vision is better than the ishihara test. Clin Exp Ophthalmol 89:73\u201380. https:\/\/doi.org\/10.1111\/j.1444-0938.2006.00015.x","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-020-01516-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T16:36:39Z","timestamp":1636734999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-020-01516-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s13760-020-01516-x","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Francisco P\u00e9rez-Miralles has received compensation from Almirall, Biogen Idec, Genzyme, Merk-Serono, Mylan, Novartis, Roche, Sanofi-Aventis, and Teva, outside the submitted work. Bonaventura Casanova has received compensation from Novartis, Roche, Biogen, Merk, Teva, and Sanofi outside the submitted work. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}